Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, with special attention for BRCA1 and BRCA2 mutation carriers: A critical review of the literature

Cancer Treatment Reviews

Volumn 41, Issue 2, 2015, Pages 187-196

  Drooger, Jan C ^a,b   Hooning, Maartje J ^a   Seynaeve, Caroline M ^a   Baaijens, Margreet H A ^a   Obdeijn, Inge Marie ^a   Sleijfer, Stefan ^a   Jager, Agnes ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b IKAZIA HOSPITAL   (Netherlands)

Author keywords

BRCA mutation; Breast cancer; Carcinogenicity; Diagnostic radiation; Radiotherapy

Indexed keywords

AGE; BRCA2 GENE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RISK; CANCER SCREENING; CARCINOGENESIS; DIAGNOSTIC IMAGING; DOUBLE STRANDED DNA BREAK; FEMALE; FOLLOW UP; GENE; GENE MUTATION; HETEROZYGOTE; HUMAN; IONIZING RADIATION; MAMMOGRAPHY; MASTECTOMY; PRIMARY TUMOR; RADIATION DOSE; RADIATION RESPONSE; REVIEW; ADJUVANT THERAPY; ADVERSE EFFECTS; BREAST NEOPLASMS; GENETIC PREDISPOSITION; MUTATION; NEOPLASMS, SECOND PRIMARY; RADIATION INJURIES; RADIOGRAPHY; RISK FACTOR; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; MAMMOGRAPHY; MUTATION; NEOPLASMS, SECOND PRIMARY; RADIATION INJURIES; RADIATION, IONIZING; RADIOTHERAPY, ADJUVANT; RISK FACTORS;

EID: 84921747572     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2014.12.002     Document Type: Review

References (64)

1. Clarke M., Collins R., Darby S., Davies C., Elphinstone P., Evans E., et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 366:2087-2106.
2. Darby S., McGale P., Correa C., Taylor C., Arriagada R., Clarke M., et al. Effects of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10801 women in 17 randomised trials. Lancet 2011, 378:1707-1716.
3. McGregor H., Land C.E., Choi K., Tokuoka S., Liu P.I., Wakabayashi T., et al. Breast cancer incidence among atomic bomb survivors, Hiroshima and Nagasaki, 1950-1969. J Natl Cancer Inst 1977, 59(3):799-811.
4. Land C.E. Studies of cancer and radiation dose among atomic bomb survivors. The example of breast cancer. JAMA 1995, 274:402-407.
5. Land C.E., Tokunaga M., Koyama K., Soda M., Preston D.L., Nishimori I., et al. Incidence of female breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950-1990. Radiat Res 2003, 160:707-717.
6. Preston D.L., Ron E., Tokuoka S., Funamoto S., Nishi N., Soda M., et al. Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat Res 2007, 168(1):1-64.
7. Howe G.R., McLaughlin J. Breast cancer mortality between 1950 and 1987 after exposure to fractionated moderate-dose-rate ionizing radiation in the Canadian fluoroscopy cohort study and a comparison with breast cancer mortality in the atomic bomb survivors study. Radiat Res 1996, 145:694-707.
8. Boice J.D., Harvey E.B., Blettner M., Stovall M., Flannery T. Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med 1992, 326:781-785.
9. Ronckers C.M., Doody M.M., Lonstein J.E., Stovall M., Land C.E. Multiple diagnostic X-rays for spine deformities and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2008, 17:605-613.
10. Preston D.L., Mattsson A., Holmberg E., Shore R., Hildreth N.G., Boice J.D. Radiation effects on breast cancer risk: a pooled analysis of eight cohorts. Radiat Res 2002, 158:220-235.
11. van Leeuwen F.E., Klokman W.J., Hagenbeek A., Noyon R., van den Belt-Dusebout A.W., van Kerkhoff E.H.M., et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol 1994, 12:312-325.
12. Swerdlow A.J., Cooke R., Bates A., Cunningham D., Falk S.J., Gilson D., et al. Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a national cohort study. J Clin Oncol 2012, 30:2745-2752.
13. Travis L.B., Hill D., Dores G.M., Gospodarowicz M., van Leeuwen F.E., Holowaty E., et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005, 97:1428-1437.
14. Hodgson D.C., Gilbert E.S., Dores G.M., Schonfeld S.J., Lynch C.F., Storm H., et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol 2007, 25:1489-1497.
15. de Bruin M.L., Sparidans J., van 't Veer M., Noordijk E.M., Louwman M.W.J., Zijlstra J.M., et al. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. J Clin Oncol 2009, 27:4239-4246.
16. Milano M.T., Li H., Gail M.H., Constine L.S., Travis L.B. Long-term survival among patients with Hodgkin's lymphoma who developed breast cancer: a population-based study. J Clin Oncol 2010, 28:5088-5096.
17. Elkin E.B., Klem M.L., Gonzales A.M., Ishill N.M., Hodgson D., Ng A.K., et al. Characteristics and outcomes of breast cancer in women with and without a history of radiation for Hodgkin's lymphoma: a multi-institutional, matched cohort study. J Clin Oncol 2011, 29:2466-2473.
18. Broeks A., Braaf L.M., Wessels L.F.A., van de Vijver M., de Bruin M., Stovall M., et al. Radiation-associated breast tumors display a distinct gene expression profile. Int J Radiat Oncol Biol Phys 2010, 76:540-547.
19. Kavanagh J.N., Redmond K.M., Schettino G., Prise K.M. DNA double strand break repair: a radiation perspective. Antioxid Redox Signal 2013, 18:2458-2472.
20. Shrivastav M., de Haro L.P., Nickoloff J.A. Regulation of DNA double-strand break repair pathway choice. Cell Res 2008, 18:134-147.
21. Connell P.P., Kron S.J., Weichselbaum R.R. Relevance and irrelevance of DNA damage response to radiotherapy. DNA Repair (Amst) 2004, 3(8-9):1245-1251.
22. Jasin M. Homologous repair of DNA damage and tumorigenesis: the BRCA connection. Oncogene 2002, 21:8981-8993.
23. Venkitaraman A.R. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002, 108:171-182.
24. Pijpe A., Andrieu N., Easton D.F., Kesminiene A., Cardis E., Nogues C., et al. Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ 2012, 6:e5660.
25. Bucholz T.A. Radiation therapy for early-stage breast cancer after breast-conserving surgery. N Engl J Med 2013, 360:63-70.
26. Stovall M., Smith S.A., Langholz B.M., Boice J.D., Shore R.E., Andersson M., et al. Dose to the contralateral breast from radiotherapy and risk of second primary breast cancer int the WECARE study. Int J Radiat Oncol Biol Phys 2008, 72:1021-1030.
27. ICRP Publication 105 Radiation protection in medicine. Ann ICRP 2007, 376:1-63.
28. Schneider U., Sumila M., Robotka J., Gruber G., Mack A., Besserer J. Dose-response relationship for breast cancer induction at radiotherapy dose. Radiat Oncol 2011, 8(6):67.
29. Ibrahim E.M., Abouelkhair K.M., Kazkaz G.A., Elmasri O.A., Al-Foheide M. Risk of second breast cancer in female Hodgkin's lymphoma survivors: a meta-analysis. BMC Cancer 2012, 28(12):197.
30. Komoike Y., Akiyam F., Lino Y., Ikeda T., Tanaka-Akashi S., Ohsumi S., et al. Analysis of ipsilateral breast tumor recurrences after breast-conserving treatment based on the classification of true recurrences and new primary tumors. Breast Cancer 2005, 12:104-111.
31. Smith T.E., Lee D., Turner B.C., Carter D., Haffty B.G. True recurrence vs. new primary ipsilateral breast tumor relapse: an analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management. Int J Radiat Oncol Biol Phys 2000, 48:1281-1289.
32. Huang E., Bucholz T.A., Meric F., Krishnamurthy S., Mirza N.Q., Ames F.C., et al. Classifying local disease recurrences after breast conservation therapy based on location and histology. Cancer 2002, 95:2059-2067.
33. McGrath S., Antonucci J., Goldstein N., Wallace M., Mitchell C., Grills I., et al. Long-term patterns of in-breast failure in patients with early stage breast cancer treated with breast conserving therapy; a molecular based clonality evaluation. Am J Clin Oncol 2010, 33:17-22.
34. Goldstein N.S., Vicini F.A., Hunter S., Odish E., Forbes S., Kraus D., et al. Molecular clonality determination of ipsilateral recurrence of invasive breast carcinomas after breast-conserving therapy; comparison with clinical and biologic factors. Am J Clin Pathol 2005, 123:679-689.
35. Vicini F.A., Antonucci J.V., Goldstein N., Wallace M., Kestin L., Krauss D., et al. The use of molecular assays to establish definitively the clonality of ipsilateral breast tumor recurrences and patterns of in-breast failure in patients with early-stage breast cancer treated with breast-conserving therapy. Cancer 2007, 109:1264-1272.
36. Viani G.A., Stefano E.J., Afonso S.L., de Fendi L.I., Soares F.V., Leon P.G., et al. Breast-conserving surgery with or without radiotherapy in women with ductal carcinoma in situ: a meta-analysis of randomized trials. Radiat Oncol 2007, 2(2):28.
37. Storm H.H., Anderson M., Boice J.D., Blettner M., Stovall M., Mouridsen H.T., et al. Adjuvant radiotherapy and risk of contralateral breast cancer. J Natl Cancer Inst 1992, 84:1245-1250.
38. Gao X., Fisher S.F., Emami B. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys 2003, 4:1038-1045.
39. Hooning M.J., Aleman B.M.P., Hauptmann M., Baaijens M.H.A., Klijn J.G.M., Noyon R., et al. Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer. J Clin Oncol 2008, 26:5561-5568.
40. Ronckers C.M., Erdmann C.A., Land C.E. Radiation and breast cancer: a review of current evidence. Breast Cancer Res 2005, 7:21-32.
41. Brooks J.D., Boice J.D., Stovall M., Reiner A.S., Bernstein L., John E.M., et al. Reproductive status at first diagnosis influences risk of radiation-induced second primary contralateral breast cancer in the WECARE study. Int J Radiat Oncol Biol Phys 2012, 84:917-924.
42. Antoniou A., Pharoah P.D.P., Narod S., Risch H.A., Eyfjord J.E., Hopper J.L., et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003, 72:1117-1130.
43. Mavaddat N., Peock S., Frost D., Ellis S., Platte R., Fineberg E., et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 2013, 105:812-822.
44. Brekelmans C.T.M., Tilanus-Linthorst M.M.A., Seynaeve C., vd Ouweland A., Menke-Pluymers M.B.E., Bartels C.C.M., et al. Tumor characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer 2007, 43:867-876.
45. Haffty B.G., Harrold E., Khan A.J., Pathare P., Smith T., Turner B.C., et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 2002, 359:1471-1477.
46. Chen S., Parmigiani G. Meta-analysis of BRCA1/2 penetrance. J Clin Oncol 2007, 25:1329-1333.
47. Narod S.A., Lubinski J., Ghadirian P., Lynch H.T., Moller P., Foulkes W.D., et al. Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet Oncol 2006, 7:402-406.
48. Goldfrank D., Chuai S., Bernstein J.L., Ramon y Cajal T., Lee J.B., Alonso M.C., et al. Effect of mammography on breast cancer risk in women with mutations in BRCA1 or BRCA2. Cancer Epidemiol Biomarkers Prev 2006, 15:2311-2313.
49. John E.M., McGuire V., Thomas D., Haile R., Ozcelik H., Milne R.L., et al. Diagnostic chest X-rays and breast cancer risk before age 50 years for BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkes Prev 2013, 22:1547-1556.
50. Andrieu N., Easton D.F., Chang-Claude J., Rookus M.A., Brohet R., Cardis E., et al. Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GE0-HEBON, and IBCCS collaborators' group. J Clin Oncol 2006, 24:3361-3366.
51. Gronwald J., Pijpe A., Byrski T., Huzrski T., Stawicka M., Cybulski C., et al. Early radiation exposure and BRCA1-associated breast cancer in young women from Poland. Breast Cancer Res Treat 2008, 112:581-584.
52. Lecarpentier J., Nogues C., Mouret-Fourme E., Stoppa-Lyonnet D., Lasset C., Caron O., et al. Variation in breast cancer risk with mutation position, smoking, alcohol, and chest X-ray history, in the French National BRCA1/2 carrier cohort (GENEPSO). Breast Cancer Res Treat 2011, 130:927-938.
53. Berrington de Gonzalez A., Berg C.D., Visvanathan K., Robson M. Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers. J Natl Cancer Inst 2009, 101:205-209.
54. Greuter M.J.W., Jansen-van der Weide M.C., Jacobi C.E., Oosterwijk J.C., Jansen L., Oudkerk M., et al. The validation of a simulation model incorporating radiation risk for mammography breast cancer screening in women with a hereditary-increased breast cancer risk. Eur J Cancer 2010, 46:495-504.
55. Lowry K.P., Lee J.M., Kong C.Y., McMahon P.M., Gilmore M.E., Cott Chubiz J.E., et al. Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers, a comparative effectiveness analysis. Cancer 2012, 118:2021-2030.
56. Metcalfe K., Lynch H.T., Ghadirian P., Tung N., Kim-Sing C., Olopade O.I., et al. Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 2011, 127:287-296.
57. Seynaeve C., Verhoog L.C., van de Bosch L.M.C., van Geel A.N., Menke-Pluymers M., Meijers-Heijboer E.J., et al. Ipsilateral breast tumor recurrence in hereditary breast cancer following breast-conserving therapy. Eur J Cancer 2004, 40:1150-1158.
58. Kirova Y.M., Stoppa-Lyonnet D., Savignoni A., Sigal-Zafrani B., Fabre N., Fourquet A. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer 2005, 41:2304-2311.
59. Garcia-Etienne C.A., Barile M., Gentilini O.D., Botteri E., Rotmensz N., Sagona A., et al. Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer?. Ann Surg Oncol 2009, 16:3380-3387.
60. Pierce L.J., Phillips K., Griffith K.A., Buys S., Gaffney D.K., Moran M.S., et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat 2010, 121:389-398.
61. Robson M., Svahn T., McCormick B., Borgen P., Hudis C.A., Norton L., et al. Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2. Cancer 2005, 103:44-51.
62. Metcalfe K., Gershman S., Lynch H.T., Ghadirian P., Tung N., Kim-Sing C., et al. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carries. Br J Cancer 2011, 104:1384-1392.
63. Bernstein J.L., Thomas D.C., Shore R.E., Robson M., Boice J.D., Stovall M., et al. Contralateral breast cancer after radiotherapy among BRCA1 and BRCA1 mutation carriers: a WECARE study report. Eur J Cancer 2013, 49:2979-2985.
64. Broeks A., Braaf L.M., Huseinovic A., Nooijen A., Urbanus J., Hogervorst F.B.L., et al. Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study. Breast Cancer Res 2007, 9:R26.